Exelixis shares jump after team up with Bristol-Myers on cancer trials
February 27, 2017 at 12:02 PM EST
Exelixis says it will evaluate its cancer drug Cabometyx with Opdivo, Bristol's PD-1 immune checkpoint inhibitor.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.